Xbira
Xbira (Abiraterone 250 mg) — Cipla CYP17 inhibitor for metastatic castration-resistant prostate cancer. Co-administered with prednisolone 5 mg twice daily to prevent mineralocorticoid excess.
✓ Ιατρικά ελεγμένο από Morgan Ellis — Ερευνητής Φαρμακευτικής · 8 χρόνια εμπειρία · Τελευταία αναθεώρηση: Μάιος 2026
Quick Answer
Xbira — Abiraterone Acetate 250 mg (Cipla Inc). CYP17 inhibitor — blocks androgen synthesis in testes, adrenals, and tumour. Used with prednisolone 5 mg twice daily (prevents mineralocorticoid excess) for metastatic castration-resistant or castration-sensitive prostate cancer.
Αυτό που λαμβάνετε με την MedsBase:
- WHO-GMP certified manufacturer
- Discreet plain-envelope packaging
- Παγκόσμια αποστολή
- Rated by 1,400+ customers (read reviews)
📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.
Γιατί να παραγγείλετε από τη MedsBase
Xbira ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
Abiraterone causes mineralocorticoid excess (hypertension, hypokalaemia, fluid retention) — co-administered prednisolone 5 mg BID mitigates this. Monitor BP every 2 weeks first 3 months. Severe hepatotoxicity reported — baseline + monthly LFTs first 3 months. Caution in heart failure / pre-existing cardiac disease.
Συχνές Ερωτήσεις
When is this used?
CYP17 inhibitor — blocks androgen synthesis in testes, adrenals, and tumour. Used with prednisolone 5 mg twice daily (prevents mineralocorticoid excess) for metastatic castration-resistant or castration-sensitive prostate cancer.
Side effects to watch?
Hot flushes, gynaecomastia, fatigue, sexual dysfunction (anti-androgen class effect). Drug-specific monitoring as outlined in the safety boxes above.
Drug interactions?
Vary by molecule — abiraterone is CYP3A4 substrate; bicalutamide is CYP3A4 substrate. Always disclose all medications. Strong CYP3A4 inhibitors/inducers significantly affect levels.
When should it be stopped?
On disease progression, intolerable toxicity, or successful response with planned treatment break. Always specialist-decided — abrupt cessation can result in transient PSA rise (withdrawal response) which is generally not concerning.
PSA monitoring?
PSA every 1-3 months while on therapy. Rising PSA on castration suggests castration-resistance — may need switch to second-line agents (abiraterone, enzalutamide, docetaxel).
Combined androgen blockade?
LHRH agonist (goserelin, leuprolide) + bicalutamide is a common combination. Maximal androgen blockade has modest survival benefit over LHRH alone.
Bone health?
Long-term androgen deprivation accelerates bone loss. Add a bisphosphonate (zoledronic acid) or denosumab in osteopenia/osteoporosis. Calcium and vitamin D supplementation.
Pregnancy?
Anti-androgens are teratogenic — partners must use effective contraception during therapy. Most relevant for younger men with localised disease.
What if I miss a dose?
Take when you remember if same day; otherwise skip. Specialist may have specific guidance for missed doses depending on regimen.
Cardiovascular monitoring?
Mandatory for fosfestrol; advised for abiraterone (BP, fluid retention, electrolytes); routine for bicalutamide (occasional CV review).
Other Cancer & Anti-Androgen Therapy
- Calutide — bicalutamide 50 mg — alternative anti-androgen brand
- Xbira — abiraterone 250 mg — CYP17 inhibitor for mCRPC
- Honvan — fosfestrol 120 mg — diethylstilbestrol diphosphate
- Estramustine — estramustine phosphate — alkylator for hormone-refractory disease
- Zoldria — zoledronic acid IV for bone metastases
More options in Anti Cancer Medication
Ταξινομημένα σύμφωνα με τον όγκο παραγγελιών στο MedsBase — τι επιλέγουν άλλοι πελάτες σε αυτήν την κατηγορία.
| Ισχύς | 250 mg |
|---|---|
| Ποσότητα | 120 Tablet/s, 240 Tablet/s, 360 Tablet/s |
| Pharma Form | Tablet/s |
| Manufacturer | Cipla Inc |
| Treatment | Anti Cancer |
| Generic Brand | Abiraterone Acetate |
Xbira
Ερωτήσεις & Απαντήσεις
Xbira
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές